Use and impact of high intensity treatments in patients with traumatic brain injury across Europe: a CENTER-TBI analysis by Huijben, Jilske A et al.
Huijben et al. Crit Care           (2021) 25:78  
https://doi.org/10.1186/s13054-020-03370-y
RESEARCH
Use and impact of high intensity treatments 
in patients with traumatic brain injury 
across Europe: a CENTER-TBI analysis
Jilske A. Huijben1* , Abhishek Dixit2, Nino Stocchetti3,4, Andrew I. R. Maas5, Hester F. Lingsma1, 
Mathieu van der Jagt6, David Nelson7, Giuseppe Citerio8,9, Lindsay Wilson10, David K. Menon2, Ari Ercole2  
and the CENTER-TBI investigators and participants
Abstract 
Purpose: To study variation in, and clinical impact of high Therapy Intensity Level (TIL) treatments for elevated intrac-
ranial pressure (ICP) in patients with traumatic brain injury (TBI) across European Intensive Care Units (ICUs).
Methods: We studied high TIL treatments (metabolic suppression, hypothermia (< 35 °C), intensive hyperventilation 
 (PaCO2 < 4 kPa), and secondary decompressive craniectomy) in patients receiving ICP monitoring in the ICU stratum 
of the CENTER-TBI study. A random effect logistic regression model was used to determine between-centre varia-
tion in their use. A propensity score-matched model was used to study the impact on outcome (6-months Glasgow 
Outcome Score-extended (GOSE)), whilst adjusting for case-mix severity, signs of brain herniation on imaging, and ICP.
Results: 313 of 758 patients from 52 European centres (41%) received at least one high TIL treatment with significant 
variation between centres (median odds ratio = 2.26). Patients often transiently received high TIL therapies without 
escalation from lower tier treatments. 38% of patients with high TIL treatment had favourable outcomes (GOSE ≥ 5). 
The use of high TIL treatment was not significantly associated with worse outcome (285 matched pairs, OR 1.4, 95% CI 
[1.0–2.0]). However, a sensitivity analysis excluding high TIL treatments at day 1 or use of metabolic suppression at any 
day did reveal a statistically significant association with worse outcome.
Conclusion: Substantial between-centre variation in use of high TIL treatments for TBI was found and treatment 
escalation to higher TIL treatments were often not preceded by more conventional lower TIL treatments. The signifi-
cant association between high TIL treatments after day 1 and worse outcomes may reflect aggressive use or unmeas-
ured confounders or inappropriate escalation strategies.
Take home message: Substantial variation was found in the use of highly intensive ICP-lowering treatments across 
European ICUs and a stepwise escalation strategy from lower to higher intensity level therapy is often lacking. Further 
research is necessary to study the impact of high therapy intensity treatments.
Trial registration: The core study was registered with ClinicalTrials.gov, number NCT02210221, registered 08/06/2014, 
https ://clini caltr ials.gov/ct2/show/NCT02 21022 1?id=NCT02 21022 1&draw=1&rank=1 and with Resource Identifica-
tion Portal (RRID: SCR_015582).
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Background
Limiting the impact of secondary insults by controlling 
harmful levels of intracranial pressure (ICP) is an essen-
tial part of Traumatic Brain Injury (TBI) care in the inten-
sive care unit (ICU). Interventions used to reduce ICP are 
typically titrated to balance their clinical effect against 
their side effects, which may be significant or even life-
threatening. The intensity of such interventions can be 
quantified by the therapy intensity level (TIL) score. The 
TIL score was first introduced in 1987 [1], and has been 
revised over the years into a more advanced scoring sys-
tem [2] which was recently validated [3]. Conceptually, 
the stepwise approach to treatment of raised ICP aims to 
use low tier therapies in the first instance, reserving more 
aggressive (and hazardous) high TIL treatments only for 
when these fail.
Despite this proposed framework for rational use of 
ICP therapies, past studies have found wide variations 
between centres in their deployment [4, 5]. Some of this 
variation may reflect either therapeutic nihilism or inap-
propriately aggressive use (as high intensity treatment 
can be clinically burdensome and consumes more ICU 
resources). While some studies report efficacy of high 
TIL therapies when properly targeted in terms of patient 
group and timing [6], other publications have given rise 
to concern that they may be ineffective in improving 
ultimate outcomes, and result in increased survival with 
severe disability [7, 8].
Therefore, the aim of this study is to investigate the var-
iation in the use of high TIL therapies in clinical practice 
and explore the impact on clinical outcome in patients 
with TBI in European ICUs.
Methods
CENTER‑TBI study/ study population
Data from the Collaborative European NeuroTrauma 
Effectiveness Research in Traumatic Brain Injury 
(CENTER-TBI) study were used for this analysis (clini-
caltrials.gov NCT02210221). CENTER-TBI recruited 
patients with TBI, presenting between December 19, 
2014 and December 17, 2017 [9, 10]. Inclusion crite-
ria for the CENTER-TBI study were: A clinical diagno-
sis of TBI, an indication for brain computer tomography 
(CT) and presentation within 24  h post-injury. Patients 
with severe pre-existing neurological disorders were 
excluded. For this study we selected patients of 14 years 
and older admitted to the ICU with documented daily 
measurements on the TIL scale for the first 7 days since 
admission to the ICU and with ICP monitoring.
Therapy intensity level
In the CENTER-TBI study, the most recent TIL scale is 
used [3] which measures and quantifies the intensity of 
ICP lowering treatments (and includes common data 
elements harmonized with the paediatric TIL scale [2]). 
The TIL scale consists of 8 ICP treatment modalities 
with corresponding scores for intensity, assessed daily 
[3] (Additional file 1: Supplement 1). High intensity ICP-
lowering treatment is indicated by the use of one or more 
of the four treatments representing maximum therapy 
intensity on the TIL scale: Barbiturates (or high dose 
sedation) for metabolic (e.g. burst) suppression, second-
ary decompressive craniectomy, intensive hyperventi-
lation to  PaCO2 < 4  kPa, and hypothermia < 35  °C. We 
refer to patients who received any of these treatments at 
any point in time during their ICU stay as the ‘high TIL’ 
group. In addition, we excluded patients with decompres-
sive craniectomy on day 1 (i.e. primary decompressive 
craniectomy) as such patients are likely to have a different 
pathophysiological trajectory and ICP therapy require-
ments due to a fundamental difference in intracranial 
compliance at the start of their ICU course. Such patients 
are also likely to be a distinct clinical entity (decompres-
sion at the time of space occupying lesion evacuation 
rather than for intractable intracranial hypertension) so 
their exclusion ensured a homogeneous population for 
a propensity score analysis. Maximum ICP prior to high 
TIL treatment (derived from 2 hourly measurements) 
was used as a measure of ICP burden.
Outcomes
Outcomes were collected at 6-months post-injury. Func-
tional outcome was assessed on the Glasgow Outcome 
Scale-Extended (GOSE) using either an interview or 
questionnaire. Categories on the GOSE are: (1) Death, 
(2) Vegetative State, (3) Lower Severe Disability, (4) 
Upper Severe Disability, (5) Lower Moderate Disability, 
(6) Upper Moderate Disability, (7) Lower Good Recov-
ery, and (8) Upper Good Recovery. Patients in categories 
(2) and (3) on the GOSE were combined in a single cate-
gory. Health related quality of life (HRQOL) was assessed 
with the Short Form 36v2 (SF-36) and the Quality of 
Life after Brain Injury (QOLIBRI) scale. For the SF-36, 
the Physical Component Summary (PCS) and Mental 
Keywords: Therapy intensity level, Barbiturates, Hypothermia, Hyperventilation, Decompressive craniectomy, 
Traumatic brain injury
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Component Summary (MCS) are expressed as T-scores. 
The QOLIBRI Total score has a range from 0 to 100.
Statistical analyses
We stratified the high- and low TIL treatment group and 
described their baseline characteristics and outcome by 
frequency/percentages for categorical variables and by 
median and interquartile ranges (IQR) for continuous 
variables. Significant group differences were determined 
with the χ2 or Fisher’s exact test for categorical variables, 
and ANOVA or Kruskal Wallis test (non-normal distri-
butions) for continuous variables.
Missing data were imputed using multiple imputation 
(100 imputations, 5 iterations) using the MICE package 
for R statistical software (version 3.6.0) [11]. The distribu-
tion of missingness per variable (prior to imputation) is 
shown in Additional file 2: Supplement 2.
To calculate the between-centre variation in the use of 
high TIL therapies beyond that expected from case-mix 
severity and random variation, we used a random effects 
logistic regression model, with high TIL use as dependent 
variable and centre as random intercept. Covariates used 
were chosen from the extended International Mission 
for Prognosis and Analysis of Clinical Trials (IMPACT) 
prognostic model [12]. In addition, we adjusted for maxi-
mum recorded ICP values prior to high TIL treatment (as 
a surrogate for prior secondary injury and/or difficulty in 
achieving control), CT variables likely to be associated 
with the development of intracranial hypertension (brain 
herniation, cortical sulcus effacement, compression of 
one of more basal cisterns, midline shift and ventricu-
lar compression), as well as extracranial injury severity 
score (ISS; excluding the head injury component). Centre 
effects are expressed and plotted as random effects with 
corresponding confidence intervals at a log odds scale. 
We also quantified the between-centre variation with the 
median odds ratio (MOR): The MOR is a measure of the 
variance of the random effects [13]. The Nakagawa’s R2 
for mixed models was calculated to determine the vari-
ance in high TIL treatment explained by the variables in 
the model.
In previous studies, the aggressiveness of TBI manage-
ment has been quantified based on the percentage use of 
ICP monitoring in patients who satisfied Brain Trauma 
Foundation (BTF) guidelines requirements for such 
monitoring. In order to examine whether this definition 
of aggressiveness based on use of a monitoring modal-
ity actually translated into aggressive management, we 
examined whether the percentage use of ICP monitoring 
in centres was related to the random effects of the use of 
high TIL per in the centre.
Finally, to study the association between high TIL 
treatment use and outcome, a propensity score matched 
model was constructed. This analysis determines whether 
the application of any high TIL therapy resulted in incre-
mental harm (aggressiveness of treatment) beyond that 
caused by ICP elevation and case-mix severity. The 
primary outcome was the Glasgow Outcome Score-
extended (GOSE) at 6 months, dichotomized into favour-
able (GOSE > 4) and unfavourable (GOSE ≤ 4). We used 
the random effects logistic regression model above to 
determine propensity scores for high TIL use. We applied 
nearest neighbour matching to select patients with a sim-
ilar propensity scores but different treatment status. We 
compared the baseline characteristics between matched 
cases (with no missing data) and tested group differences 
(should be non-significant) and calculated the standard-
ized mean differences (which should be low) to check 
match validity. In the matched cases, we compared the 
result of high versus low TIL treatment using a logistic 
regression with 6-month unfavourable GOSE as primary 
outcome. Two sensitivity analyses were performed to 
check whether the treatments were applied appropriately 
as high TIL practice. The first of these excluded high TIL 
treatments on day 1 to more faithfully reflect escalation 
of ICP therapy and discard non-treatment confounds (for 
example, hypothermia on day 1 may be injury related). 
Secondly, we considered the possibility that the use of 
barbiturates may have simply reflected therapy to target 
early / transient difficulties in controlling in ICP, rather 
than a sustained escalation of therapy. Consequently, the 
second sensitivity analysis excluded all barbiturate use as 
a high TIL treatment.
Analyses were performed using R statistical software 
[14]. The dataset was stored and accessed using the Opal 




A total of 758 patients from 52 centres in Europe received 
ICP monitoring with documented TIL measurements 
during their ICU stay (Fig.  1, Additional file  4:  Supple-
ment 4, Additional file  6: Supplement 6). Of these, 313 
patients (41.3%) received high TIL treatments at least 
once during their ICU stay. Table  1 summarises these 
groups. Patients who received high TIL treatment were 
generally younger, had better preinjury health status, and 
suffered from more severe brain trauma. Multimodal cer-
ebral monitoring was generally more often used in high 
TIL patients.
Patients requiring high TIL treatment generally had 
longer ICU stays and had a longer duration of mechani-
cal ventilation (Table  2). Overall, high TIL and low TIL 
patients were discharged from the ICU with similar GCS 
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scores. The complication rate was similar in the two 
groups, except for metabolic complications (high TIL: 
14.0%, versus low TIL: 7.3% p = 0.004) (abnormalities in 
renal or liver function and electrolyte derangements).
Patterns of high TIL therapy use
Of the 313 patients, most received metabolic suppression 
while a minority of cases received intensive hyperventila-
tion, intensive hypothermia, or secondary decompressive 
craniectomy (Additional file 3: Supplement 3, Additional 
file  5:  Supplement 5). In general, TIL peaked after day 
2, except for hypothermia (which was most commonly 
applied on day 1). In the majority of cases receiving 
high TIL treatment, head elevation, vasopressors and 
higher dose sedation had been used, but cerebrospinal 
fluid (CSF) drainage, hyperosmolar therapies, and being 
nursed flat were recorded only in a minority of instances. 
Mean TIL scores in the high TIL group were below 10 
points.
Between centre variation
Our study included 52 centres from 18 countries in the 
CENTER-TBI study. The median number of patients per 
centre was 11.5 [IQR 5–19]. Most centres used barbitu-
rates (N = 46) while fewer centres used intensive hyper-
ventilation (N = 21), hypothermia below 35  °C (N = 32), 
and decompressive craniectomy (N = 26). Based on treat-
ment frequencies, there was a high degree of between 
centre variation in treatment choice. Overall, significant 
between centre variation beyond case mix and random 
variation (p < 0.001) was found in the use of high TIL 
treatments (MOR = 2.26). (Fig. 2, Additional file 7: Sup-
plement 7). The Nakagawa’s R2 showed that model vari-
ables ‘explained’ 8.7% of the (pseudo)variance in high TIL 
treatment use. Comparing measures of aggressiveness, 
the percentage use of ICP monitoring in patients who 
satisfied BTF guidelines was not related to the use of high 
TIL therapies by the centre (Fig. 3).
Impact of high TIL treatment on outcome
Although unfavourable outcome was more frequent in 
the high TIL group (62.5% versus 53.0%, p = 0.019)–a 
high proportion of high TIL patients nevertheless 
achieved a favourable outcome at 6  months (GOSE ≥ 5: 
N = 105; 37.5%). Mortality was significantly higher in the 
high TIL group (20.2% versus 13.3%, p = 0.016) (Fig.  4). 
The data on Health-Related Quality of Life (HRQOL) are 
less complete than the GOSE, since in addition to loss to 
follow-up there are no scores for patients who die. Both 
groups had similar scores on the SF-36v2 MCS and PCS 
and the QOLIBRI total score. (Table 2).
A total of 280 treated (high TIL) patients were well 
matched in terms of their baseline characteristics (Addi-
tional file  8: Supplement 8) and maximum ICP prior to 
TIL treatment did not differ between groups (Additional 
file 9: Supplement 9). With correction for maximum ICP 
prior to high TIL treatment; high TIL treatment was not 
significantly associated with unfavourable outcome (OR 
1.4, 95% CI [0.98–1.96], p = 0.068). However, after the 
sensitivity analyses the association with worse outcome 
became significant for high TIL after day 1 (OR 1.5 CI 
[1.1–2.2], p = 0.023) and high TIL excluding barbiturates 
(OR 2.5 CI [1.4–4.7] p = 0.004). (Table 3).
Discussion
To our knowledge, this is the first study to quantify treat-
ments using the TIL scale in real-world clinical practice 
across centres in Europe. We report substantial between-
centre variation in the choice and use of high TIL treat-
ments in patients with TBI admitted to the ICU across 
Europe. Further, we did not observe a systematic pro-
gression in therapy intensity, exhausting low-tier treat-
ments before escalating to more intensive therapies: 
Fig. 1 Flowchart: patient inclusion. This flowchart is showing the 
inclusion of high TIL patients. High TIL patients were defined as 
patients receiving any treatment during ICU stay representing 
maximum therapy intensity of the TIL scale: Barbiturates for metabolic 
suppression, (secondary) decompressive craniectomy, intensive 
hyperventilation to PaCO2 < 4 kPa, and hypothermia < 35 °C at any 
point during their ICU stay
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Table 1 Baseline patient and monitoring characteristics
Low TIL(N = 445) High TIL (N = 313) p‑value
Age (median, IQR) 51 [30.0–65.0] 41 [27.0–65.0]  < 0.001
Gender, male (N,%) 326/445 (73.3) 235/313 (75.1) 0.632
Injury severity (GCS at baseline)
Mild > = 13 (N, %) 77/414 (18.6) 29/296 (9.8) 0.002
Moderate > = 9—< 13(N, %) 78/414 (18.8) 51/296 (17.2) 0.653
Severe < 9 (N, %) 259/414 (62.6) 216/296 (73.0) 0.005
ISS without head injury (median, IQR) 10 [0.0–25.0] 13 [0.0–25.0] 0.286
CT (N,%)
 tSAH 306/367 (− 83.4) 228/253 (− 90.1) 0.023
 EDH 73/366 (− 19.9) 58/254 (− 22.8) 0.443
Marshall (N, %)
 1 11/367 (− 3) 5/253 (− 2)  < 0.001
 2 168/367 (− 45.8) 94/253 (− 37.2)
 3 30/367 (− 8.2) 57/253 (− 22.5)
 4 8/367 (− 2.2) 5/253 (− 2)
 5 2/367 (− 0.5) 2/253 (− 0.8)
 6 148/367 (− 40.3) 90/253 (− 35.6)
Preinjury ASA (N, %) 0.001
 1) Normal healthy 230/428 (− 53.7) 194/296 (− 65.5)
 2) Mild systemic disease 144/428 (− 33.6) 88/296 (− 29.7)
 3) Severe systemic disease 51/428 (− 11.9) 13/296 (− 4.4)
 4) Severe systemic disease, a constant threat to life 3/428 (− 0.7) 1/296 (− 0.3)
Cause of injury (N, %) 0.295
 Road traffic incident 212/430 (− 49.3) 148/301 (− 49.2)
 Incidental fall 166/430 (− 38.6) 106/301 (− 35.2)
 Violence/assault 15/430 (− 3.5) 18/301 (− 6)
 Suicide attempt 10/430 (− 2.3) 4/301 (− 1.3)
 Other 27/430 (− 6.3) 25/301 (− 8.3)
Prehospital1 (N, %)
 Hypoxia 89/445 (− 20) 39/313 (− 12.5) 0.009
 Hypotension 80/445 (− 18) 47/313 (− 15) 0.329
Lab1 (median, IQR)
 Hemoglobin (g/dL) 13.1 [11.6–14.4] 13.2 [11.9–14.3] 0.694
 Glucose (mmol/L) 7.9 [6.7–9.9] 7.8 [ 6.7–9.8] 0.933
Type ICP monitor (N, %) 0.511
 Ventricular 53/445 (− 11.9) 38/312 (− 12.2)
 Ventricular + inbuilt sensor 7/445 (− 1.6) 10/312 (− 3.2)
 Parenchymal 366/445 (− 82.2) 250/312 (− 80.1)
 Other 19/445 (− 4.3) 14/312 (− 4.5)
Multimodal cerebral monitoring (N, %)
 Jugular oximetry 9/445 (− 2) 20/312(− 6.4) 0.004
 Brain tissue PbtO2 84/445 (− 18.9) 65/312 (− 20.8) 0.555
 Transcranial Doppler 34/444 (− 7.7) 78/312 (− 25)  < 0.001
 Microdialysis 48/445 (− 10.8) 30/311 (− 9.6) 0.7
 Continuous EEG 21/445 (− 4.7) 38/311 (− 12.2)  < 0.001
 Electrocorticography 4/444 (− 0.9) 1/311 (− 0.3) 0.61
Systemic monitoring (N, %)
 Invasive blood pressure monitoring 432/445 (− 97.1) 306/312 (− 98.1) 0.53
 Cardiac output 74/444 (− 16.7) 80/312 (− 25.6) 0.003
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instead high tier therapies were often used early in the 
course of treatment. This was unexpected, because pro-
gressive approach to treatment is recommended by the 
Brain Trauma Foundation guidelines [16] and forms part 
of the standard protocol in previous large clinical trials. 
In line with previous observational studies, we found 
relatively infrequent use of intensive hyperventilation, 
or decompressive craniectomy [17, 18]. In contrast, we 
found a relatively liberal use of barbiturates/deep seda-
tion for metabolic suppression [19]. We found signifi-
cant between centre variation in high TIL therapy use, 
beyond that accounted for by case-mix severity and ran-
dom variation, both in terms of choice of therapy (e.g. 
use of hypothermia in a centre) and overall frequency of 
use (corrected for case-mix severity and random varia-
tion). This variation in high TIL treatment at centre-level 
suggests that, apart from disease severity, the clinical 
decision to use high TIL treatment is also based on insti-
tutional policy and culture.
After correction for ICP control, no statistically signifi-
cant association was found between the use of high TIL 
treatment and functional outcome at 6 months. However, 
when excluding high TIL treatment at day 1 or barbitu-
rates from high TIL treatment there was a statistically 
significant association with worse outcome. This may 
reflect some unquantified aspect of disease severity that 
is not captured by the available covariates but neverthe-
less translates into both TIL and outcome differences. 
Alternatively, this could mean that there is indeed some 
harm from residual high TIL therapies, in which case 
the use of these therapies before less hazardous low TIL 
options are exhausted could expose patients to unneces-
sary risks. Still, high-level evidence is lacking about the 
use of individual lower TIL therapies like CSF drainage 
and hyperosmolar fluids. This might explain why cen-
tres are cautious to apply these lower TIL treatments as 
standard use before proceeding to higher TIL treatment. 
Future studies are needed to confirm these findings as 
the sample size might have been insufficient to detect 
an association and to determine if a certain patient sub-
group might benefit. High TIL treatments were associ-
ated with increased duration of ventilation and longer 
lengths of stay although we did not find a higher compli-
cation rate, at least for the metrics recorded. While we 
matched the two groups on available factors known to 
influence outcome, it is also possible that other aspects 
of the clinical course which we could not capture are also 
important in a clinician’s decision to institute high TIL 
therapies (residual confounding).
An important finding is that a large proportion of 
patients receiving high TIL treatments nevertheless 
recovered to good functional outcome (moderate disabil-
ity to good recovery) at 6  months. High TIL treatment 
might be an appropriate final resource for patients with 
refractory high ICP values and may be beneficial in this 
group. Nevertheless, since there could be risks of such 
treatments, this emphasises the need for their rational 
use. More work is required to understand if outcome 
benefits could result from a more consistently gradated 
and progressive application of treatment intensity and/or 
a shift from institutional policies towards individualized 
medicine.
Previous studies have defined highly intensive (aggres-
sive) treatment for ICP control in different ways [4–7, 20]. 
Cnossen et al. explored various definitions for aggressive 
treatment, such as the definitions ‘use of ICP monitoring 
in more than 50% in patients meeting the BTF guidelines 
criteria’ and ‘aggressiveness based on a TIL score (any 
of the following: osmotic therapy, hyperventilation, cer-
ebrospinal fluid drainage, vasopressors for cerebral per-
fusion pressure support, hypothermia, barbiturates, and 
neurosurgical intervention)’ [4]. Bulger et al. also defined 
This table describes the baseline characteristics of patients with a high versus a low therapy intensity level (TIL). High TIL was defined as any high intensity treatment 
(decompressive craniectomy excluding day 1, barbiturates, intensive hypothermia, intensive hyperventilation) during the ICU stay. Significant group differences 
were determined by using the chi-square or Fisher’s exact test (non-normal distributions) for categorical variables and an ANOVAS or Kruskal Wallis test (non-normal 
distributions) for continuous variables
1 IMPACT, first available
ASA score: American Society of Anesthesiologists (ASA) Physical Status score,  CO2: carbon dioxide, CT: Computed tomography, CRBSI: catheter-related blood-stream 
infection EEG: electroencephalogram, GCS: Glasgow Coma Scale, ICP: intracranial pressure, ISS: injury severity score, IQR: interquartile range, PbtO2: brain tissue partial 
pressure of oxygen, TIL: therapy intensity level
Table 1 (continued)
Low TIL(N = 445) High TIL (N = 313) p‑value
 Pulse oximetry 436/445 (− 98) 303/312 (− 97.1) 0.6
 End tidal  CO2 335/444 (− 75.5) 213/312 (− 68.3) 0.036
 Central venous pressure 261/444 (− 58.8) 190/312 (− 60.9) 0.612
Mechanical ventilation
 Present 416/441 (− 94.3) 287/312 (− 92) 0.261
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aggressiveness as ‘the use of ICP monitoring according 
to the BTF guidelines in more than 50% of patients’ [5]. 
However, this definition of aggressiveness (use of ICP 
monitoring) did not correlate with measured aggressive-
ness of therapy in our study, defined in our dataset as 
the likelihood of using high TIL therapies. We conclude 
that the previous use of higher use of ICP monitoring as 
a marker of aggressive TBI management in a centre may 
be flawed.
Several recent large trials have studied the impact on 
outcome of individual high TIL treatments, such as 
decompressive craniectomy [6, 8] or intensive hypo-
thermia [21], but there is a need to assess other haz-
ardous ICP-directed therapies (such as intensive 
hyperventilation and barbiturate coma) in this setting 
Table 2 Patient outcomes
This table describes the outcomes of patients stratified by high versus a low therapy intensity level treatment. High TIL was defined as any high intensity treatment 
(decompressive craniectomy excluding day 1, barbiturates, intensive hypothermia, intensive hyperventilation) during ICU stay. Significant group differences were 
determined by using the chi-square or Fisher’s exact test (non-normal distributions) for categorical variables and an ANOVA or Kruskal Wallis test (non-normal 
distributions) for continuous variables
1 Significant variation in proportion of abnormal lab values for high TIL vs. low TIL patients, i.e. creatinine (24.8% vs. 20.1%, p < 0.001), sodium (50.1% vs. 39.7%, 
p < 0.001), ASAT (49.1% vs 49.2%, p = 0.865), and ALAT (39.3% vs. 37.9%, p = 0.020)
CRBSI: Catheter-related bloodstream infection, DVT: Deep Venous Thrombosis, GCS: Glasgow Coma Scale, GOSE: Glasgow Outcome Scale Extended, ICU: Intensive 
Care Unit, Qolibri: Quality of life after brain injury total score, SF-36 MCS: Short Form-36v2 Mental Component Summary, SF-36 PCS: Short Form-36v2 Physical 
Component Summary, TIL: therapy intensity level, VAP: ventilator acquired pneumonia
Low TIL (N = 445) High TIL (N = 313) p‑value
General ICU outcomes (median, IQR)
 Length of ICU stay 11 [5.8–19] 17 [10–26]  < 0.001
 Duration of ventilation 8 [4.0–15] 14 [8–21]  < 0.001
 Time to obey commands 6 [2.0–11] 13 [21]  < 0.001
ICU systemic complications (N, %)
 Cardiovascular 52/441 (− 11.8) 34/307 (− 11.1) 0.853
 CRBSI 20/441 (− 4.5) 7/307 (− 2.3) 0.154
 DVT 5/441 (− 1.1) 7/307 (− 2.3) 0.351
 Pulmonary embolus 10/441 (− 2.3) 5/307 (− 1.6) 0.728
 Metabolic1 32/441 (− 7.3) 43/307 (− 14) 0.004
 Pressure sores 20/441(− 4.5) 15/307 (− 4.9) 0.962
 Respiratory failure 156/441 (− 35.4) 123/307 (− 40.1) 0.219
 VAP 107/441 (− 24.3) 85/307 (− 27.7) 0.332
 UTI 36/441 (− 8.2) 30/307 (− 9.8) 0.527
 Other 38/441 (− 8.6) 32/307 (− 10.4) 0.48
ICU discharge outcomes
 ICU mortality (N, %) 59/442 (− 13.3) 62/307 (− 20.2) 0.016
GCS discharge score
 Mild > = 13 (N, %) 121/445 (− 27.2) 75/313 (− 24) 0.36
 Moderate > = 9—< 13(N, %) 13/445 (− 2.9) 13/313 (− 4.2) 0.475
 Severe < 9 (N, %) 311/445 (− 69.9) 225/313 (− 71.9) 0.607
Outcomes after 6 months
 GOSE 344 /381 (− 90.3) 262/280 (− 93.6) 0.171
 GOSE < 8 (N, %) 202/381 (− 53) 175/280 (− 62.5) 0.019
 GOSE < 5 (N, %) 107/381 (− 28.1) 63/280 (− 22.6)
 GOSE = 1 (N, %)
Qolibri
 Impaired (< 52) (N, %) 32/ 173 (− 18.5) 29/121 (− 24) 0.321
SF-36 MCS
 Impaired (< 40) (N, %) 57/173 (− 32.9) 40/117 (− 34.2) 0.926
SF-36 PCS
 Impaired (< 40) (N, %) 57/173 (− 32.9) 40/117 (− 34.2) 0.926
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[16]. Our analysis targeted integrated assessment of all of 
these therapies, but the heterogeneity and lack of a uni-
form tiered approach to their use suggest that compara-
tive effectiveness research (CER) approaches to exploring 
these therapies may have problems.
This study has a number of limitations that need to be 
discussed. First, the definition of a high TIL treatment is 
to some extent arbitrary as it is based on expert opinion 
rather than concrete outcome data. We considered meta-
bolic suppression as a second-tier treatment, based on 
the recommendation in BTF guidelines that barbiturates 
should be considered a second-tier therapy (for raised 
ICP refractory to maximum treatment) [16]. However, 
our data suggest that in many centres others might con-
sider this a first-tier/early therapy, in keeping with results 
from our Provider Profiling exercise [22]. In addition, we 
have no data on whether short durations of metabolic 
suppression in the early phase of illness carry the same 
risks as prolonged metabolic suppression employed as a 
treatment for refractory ICP in a later stage. Second, we 
do not have detailed data on how carefully these treat-
ments were implemented, which is a significant omission. 
For example, the methods and rates of cooling or re-
warming could affect both the efficacy and harm associ-
ated with intensive hypothermia. Finally, incomplete data 
on ICP monitoring made it difficult to accurately define a 
metric for poor ICP control before escalation of therapy 
and hence made propensity matching difficult. As poorly 
controlled ICP is likely to be a driver for escalation of 
therapy (or for continuing high TIL therapy), and also a 
marker of poor outcome, the absence of these data makes 
a rigorous covariate-adjusted comparison of high and 
low- TIL therapy groups difficult.
Future directions
Further work will be needed to explore the process 
by which clinical decisions to proceed to more inten-
sive treatments are undertaken and determine the best 
Fig. 2 Between-centre variation in high TIL use. This figure shows the between-centre variation in the use of high TIL (Therapy Intensity Level) 
treatment. The use of high TIL per centre was adjusted for case-mix severity, brain herniation on imaging, maximum ICP value at the day of the 
start of high TIL treatment and random variation per centre with a random effects logistic regression model. For each centre, the random effect 
with corresponding 95% CI is plotted (average effect is log odds of zero). The MOR reflects the odds of high TIL treatment between two randomly 
selected centres for patients with the same case-mix severity (a higher MOR reflects larger between-centre variation) The MOR represents the 
median odds ratio; the higher the MOR the larger the between-centre variation (a MOR of 1 reflects no variation)
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way that hazardous therapies should be introduced in 
a rational tiered treatment plan. The evidence base to 
choose a particular high TIL treatment over another is 
limited, since the evidence on benefit from these thera-
pies is either absent or conflicting [6–8, 21]. This lack of 
evidence helps to explain high between-centre variation 
in choice of treatment, and currently means that the 
initiation and choice of high TIL interventions is only 
driven by patient characteristics to a very limited extent 
and is primarily based on institutional policies. A better 
identification of subgroups of patients who benefit from 
such therapies would allow better targeting of either 
individual interventions, or high intensity therapies in 
general. We also need to explore whether more rigor-
ous ICP control, with higher intensity therapies, may, in 
a subgroup of patients, prevent refractory intracranial 
hypertension, reduce ICU stay, and possibly improve 
outcome. The search for patient and monitoring char-
acteristics that identify such a subgroup could allow a 
precision medicine approach to ICP management.
Conclusions
We show substantial variation amongst European cen-
tres in the choice and use of ICP-lowering treatments 
for patients with TBI. We found a no statistically sig-
nificant association between the use of high TIL ther-
apies and worse outcome after 6  months although a 
significant association did become apparent when day 1 
or high dose sedation was excluded. However, this dif-
ference may have been flawed because of incomplete 
Fig. 3 Definitions of aggressiveness. This figure illustrates the concordance between two definitions to identify aggressiveness of centers. On 
the x-axis is the definition of aggressiveness according to previous studies: the percentage of patients receiving ICP monitoring according to the 
BTF guidelines (GCS < 8 and abnormal CT, or normal CT and 2 or more of the following: hypotension, age > 40 years, unilateral or bilateral motor 
posturing, or systolic blood pressure (BP) < 90 mmHg). This percentage ICP monitoring was calculated in the ICU database (including all patients). 
On the y-axis is the definition of aggressiveness according to our study: the random effects of high TIL treatment per centers (log odds of receiving 
high TIL treatment). The upper right quadrant shows the centers that are both identified as aggressive by the previous definition (threshold 50% 
ICP monitoring) and the definition in our study (threshold random effect of zero).The lower left quadrant shows the centers that are identified as 
non-aggressive centers by both definitions. The two other quadrants show a discrepancy between the definitions of aggressiveness. Overall, there is 
no relationship between aggressiveness defined using ICP monitoring rates and actual use of aggressive therapies for ICP control
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propensity matching of the high TIL and control 
groups due to unmeasured covariates. In any case, 
our results do not support a nihilistic view of patients 
who receive high TIL treatments; one third of high TIL 
patients achieved a favourable functional outcome, and 
high TIL treatment might have contributed to this. Fur-
ther studies need to confirm whether and when high 
TIL treatments can be used as a safe final resort. More 
consistent use of low-tier treatments before escalat-
ing management to high TIL therapies, and data that 
support a rational choice of high TIL therapies, could 
both contribute to improved clinical outcome.
Supplementary information
is available for this paper at https ://doi.org/10.1186/s1305 4-020-03370 -y.
Additional file 1. Therapy Intensity Level scale. Description: This table 
shows the scoring of the Therapy Intensity Level (TIL) as recorded in the 
CENTER-TBI study. Derived from Zuercher et al. [3].  High TIL therapies are 
shown in bold.
Additional file 2. Missing data. Description: This figure shows the propor-
tion of missing data in the original data (before imputation). In the left 
panel the proportion of missingness per variable is shown. In the combi-
nation plot (grid) all patterns of missing (red) and observed data (blue) are 
shown. For example, the bottom row shows all patients with complete 
data, above that the patients with the combination missing data for Hb 
and gluc, ect. The bars on the right of the combination plot show the 
frequency of occurrence of the combinations.
Additional file 3. Treatments on the TIL scale (all patients).Description: 
This table shows the number and percentages of ICP-monitored patients 
receiving ICP-lowering treatments on the TIL scale. Each row shows the 
number of patients (frequency) that receive that treatment (a patient 
could receive multiple treatments per topic).
Additional file 4. Daily TIL scores. Description: This figure shows the 
daily high TIL scores (cumulative score of the high TIL treatments) plotted 
against the daily low TIL scores (cumulative score for low TIL treatments). 
It shows that at the same high TIL scores a variety of low TIL treatment 
(scores) is applied (in some cases even no low TIL treatment). Also, the fig-
ure shows mainly at day 3 (dark green)  higher TIL treatments are applied 
including higher low TIL scores.
Additional file 5. Treatments on the TIL scale (high TIL patients). Descrip-
tion: This table shows the number and percentages of high TIL patients 
receiving ICP-lowering treatments on the TIL scale. Each row shows the 
number of patients (frequency) that receive that treatment (a patient 
could receive multiple treatments per topic) Bolt treatment are regarded 
as high TIL treatment.
Additional file 6. Higher tier ICP-lowering treatments in patients receiv-
ing high TIL treatment. Description: This figure shows the proportion 
of patients that receive first and second tier treatments of the high TIL 
patients across 7 days at the Intensive Care Unit.
Additional file 7. Variation in high TIL treatment percentages across cen-
tres (centre-level). Description: This table describes the between-centre 
variation for high TIL treatments across the days. The number of centres 
are the centres that actually apply the individual treatments. The mean 
percentage represents the mean percentage of patients across centres 
Fig. 4 Functional outcome at 6 months. This figure shows the 
functional outcome (GOSE) at 6 months for patients who receive 
low therapy and high therapy intensity. GOSE 1: death, 2: vegetative 
state, 3: severe disability lower, 4: severe disability upper, 5: moderate 
disability lower, 6: moderate disability upper, 7: good recovery lower, 
8: good recovery upper. Patients in categories (2) and (3) on the GOSE 
were combined in a single category. GOSE: Glasgow Outcome Scale 
Extended, TIL: Therapy Intensity Level were combined in a single 
category. GOSE: Glasgow Outcome Scale Extended, TIL: Therapy 
Intensity Level
Table 3 Adjusted outcome after high TIL versus low TIL treatment (propensity score matched model)
This table describes the differences in outcome after receiving high Therapy Intensity Level (TIL) treatment versus low TIL treatment. Overall high TIL was defined 
as any high intensity treatment (decompressive craniectomy excluding day 1, barbiturates, intensive hypothermia, intensive hyperventilation) during ICU stay. The 
primary outcome is the GOSE after 6 months. We used a multivariate propensity score matched model with correction for centre effects (random intercept). Nearest 
neighbour matching was used to select patients with the similar propensity scores and different treatment status. Covariates used for matching were IMPACT 
variables and ‘ISS without head injury ‘and in the final model we corrected for maximum ICP values prior to treatment. For the sensitivity analyses, we only selected 
patient with high TIL treatments after day 1 or excluded patients receiving barbiturates
CI: confidence interval, GOSE: Glasgow Outcome Scale Extended, ICP: intracranial pressure, ICU: intensive care unit, Nr: number of matches, OR: odds ratio, TIL: therapy 
intensity level
Main analysis Sensitivity analyses
High TIL treatment High TIL treatment after day 1 High TIL treatment 
excluding barbiturates
Nr OR [95% CI] p Nr OR [95% CI] p Nr OR [95% CI] p
Unfavourable GOSE ≤ 4 280 1.4 [1.0–2.0] 0.068 250 1.5 [1.1–2.2] 0.023 114 2.5 [1.4–4.7] 0.004
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that receive the therapy, while the IQR and min-max represents the varia-
tion in treatment use between centres.
Additional file 8. Baseline characteristics matched dataset. Description:  
This table describes the baseline characteristics of the matched cases with 
complete data  (as the dataset was imputed, this table could only be com-
pleted for complete cases). Significant group differences were determined 
by using the chi-square or Fisher’s exact test (non-normal distributions) 
for categorical variables and an ANOVA or Kruskal Wallis test (non-normal 
distributions) for continuous variables.
Additional file 9. Maximum ICP values prior to start high TIL use per treat-
ment group. Description: This figure shows the differences in maximum 
ICP values prior to high TIL treatment between patients with a high TIL (1) 
versus a low TIL treatment (0).  The median ICP for low TIL is 22 [16-28] and 
for high TIL 22 [16-27]. This difference is not statistically significant.
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